CrystaX’s tagline is accelerating drug discovery. The company aims to reduce the time from the identification of target gene sequences to the synthesis of lead drug candidates, using an integrated and automated discovery platform. CrystaX has primarily focused on oncology and has two pipeline programs in this field, a chromatin-modifying enzyme inhibitor research program and a molecular chaperones research program.